8-K current report · filed Aug 5, 2026

Lilly (Eli) (LLY) 8-K Current Report: August 5, 2026

Item EX-99.1Item 2.02LLY overview

Short answer

Lilly (Eli) (LLY) filed an 8-K current report with the SEC on August 5, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Q2 2026 financial results announced for the quarter ended June 30, 2026.

Lilly (Eli) 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q2 2026 financial results announced for the quarter ended June 30, 2026
  • Exhibit 99.1 contains the earnings release and the company’s reported operating results
  • Investor focus: quarterly performance update for revenue, earnings, guidance and product trends in the accompanying release

Item EX-99.1 · Exhibit EX-99.1

  • Q2 revenue $22.974B, up 48%, with volume up 60% despite realized-price decline of 13%
  • Mounjaro revenue $9.943B, up 91%, and Zepbound revenue $4.928B, up 46%, reinforcing incretin concentration
  • Non-GAAP EPS $8.38, up 33%, while $3.03 per share of acquired IPR&D charges depressed reported profitability
  • 2026 revenue guidance raised to $85B-$87B, but EPS guidance narrowed to $35.50-$36.50 after acquisition charges
  • Retatrutide Phase 3 package complete, with U.S. obesity filing planned for Q1 2027 and $4.5B added to Indiana manufacturing capex

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Lilly (Eli) 8-K filings

Get the next LLY 8-K as it lands

Follow LLY for push alerts, or ask the research agent what this filing means.